Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Renato Marchiori Bakos
Based on 10 articles published since 2010
(Why 10 articles?)
||||

Between 2010 and 2020, Renato Bakos wrote the following 10 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline Brazilian guidelines for diagnosis, treatment and follow-up of primary cutaneous melanoma - Part II. 2016

Castro, Luiz Guilherme Martins / Bakos, Renato Marchiori / Duprat Neto, João Pedreira / Bittencourt, Flávia Vasques / Di Giacomo, Thais Helena Bello / Serpa, Sérgio Schrader / Messina, Maria Cristina de Lorenzo / Loureiro, Walter Refkalefsky / Macarenco, Ricardo Silvestre e Silva / Stolf, Hamilton Ometto / Gontijo, Gabriel. ·Hospital Israelita Albert Einstein, SP, Brazil. · Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. · Departamento de Câncer de Pele, A. C. Camargo Cancer Center, São Paulo, SP, Brazil. · Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. · Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil. · Universidade Estadual do Pará, Belém, PA, Brazil. · Universidade Estadual Paulista "Júlio de Mesquita Filho", Botucatu, SP, Brazil. ·An Bras Dermatol · Pubmed #26982779.

ABSTRACT: The last Brazilian guidelines on melanoma were published in 2002. Development in diagnosis and treatment made updating necessary. The coordinators elaborated ten clinical questions, based on PICO system. A Medline search, according to specific MeSH terms for each of the 10 questions was performed and articles selected were classified from A to D according to level of scientific evidence. Based on the results, recommendations were defined and classified according to scientific strength. The present Guidelines were divided in two parts for editorial and publication reasons. In this second part, the following clinical questions were answered: 1) which patients with primary cutaneous melanoma benefit from sentinel lymph node biopsy? 2) Follow-up with body mapping is indicated for which patients? 3) Is preventive excision of acral nevi beneficious to patients? 4) Is preventive excision of giant congenital nevi beneficious to patients? 5) How should stages 0 and I primary cutaneous melanoma patients be followed?

2 Guideline Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I. 2015

Castro, Luiz Guilherme Martins / Messina, Maria Cristina / Loureiro, Walter / Macarenco, Ricardo Silvestre / Duprat Neto, João Pedreira / Di Giacomo, Thais Helena Bello / Bittencourt, Flávia Vasques / Bakos, Renato Marchiori / Serpa, Sérgio Schrader / Stolf, Hamilton Ometto / Gontijo, Gabriel. ·Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. · Universidade Estadual do Pará, Belém, SP, Brazil. · Departamento de Câncer de Pele, A. C. Camargo Cancer Center, São Paulo, SP, Brazil. · Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. · Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. · Universidade Estácio de Sá, Rio de Janeiro, RJ, Brazil. · Universidade Estadual Paulista, Botucatu, SP, Brazil. ·An Bras Dermatol · Pubmed #26734867.

ABSTRACT: The last Brazilian guidelines on melanoma were published in 2002. Development in diagnosis and treatment made updating necessary. The coordinators elaborated ten clinical questions, based on PICO system. A Medline search, according to specific MeSH terms for each of the 10 questions was performed and articles selected were classified from A to D according to level of scientific evidence. Based on the results, recommendations were defined and classified according to scientific strength. The present Guidelines were divided in two parts for editorial and publication reasons. In the first part, the following clinical questions were answered: 1) The use of dermoscopy for diagnosis of primary cutaneous melanoma brings benefits for patients when compared with clinical examination? 2) Does dermoscopy favor diagnosis of nail apparatus melanoma? 3) Is there a prognostic difference when incisional or excisional biopsies are used? 4) Does revision by a pathologist trained in melanoma contribute to diagnosis and treatment of primary cutaneous melanoma? What margins should be used to treat lentigo maligna melanoma and melanoma in situ?

3 Article Tropomyosin-Related Kinase Receptor and Neurotrophin Expression in Cutaneous Melanoma Is Associated with a Poor Prognosis and Decreased Survival. 2019

Antunes, Luís Carlos Moreira / Cartell, André / de Farias, Caroline Brunetto / Bakos, Renato Marchiori / Roesler, Rafael / Schwartsmann, Gilberto. ·Graduate Program in Medical Sciences, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, luisantunes@clinicaviversm.com.br. · Hematology and Oncology Service, Santa Maria University Hospital, Federal University of Santa Maria, Santa Maria, Brazil, luisantunes@clinicaviversm.com.br. · Department of Pathology, Porto Alegre Clinical Hospital, Porto Alegre, Brazil. · Cancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre Clinical Hospital, Porto Alegre, Brazil. · Graduate Program in Medical Sciences, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. · Department of Dermatology, Porto Alegre Clinical Hospital, Porto Alegre, Brazil. · Department of Pharmacology, Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. · Department of Internal Medicine, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. ·Oncology · Pubmed #31071716.

ABSTRACT: OBJECTIVE: Normally, activation of tropomyosin-related kinase (TRK) receptors by neurotrophins (NTs) stimulates intracellular pathways involved in cell survival and proliferation. Dysregulation of NT/TRK signaling may affect neoplasm prognosis. Data on NT and TRK expression in melanomas are limited, and it is unclear whether NT/TRK signaling pathways are involved in the origin and progression of this neoplasm. METHODS: We examined whether NT/TRK expression differs across different cutaneous melanoma grades and subtypes, and whether it is associated with melanoma prognosis and survival. A cross-sectional study was performed in which the expression of TrkA, TrkB, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) was analyzed by immunohistochemistry of 154 melanoma samples. We investigated NT/TRK expression associations with prognostic factors for melanoma, relapse-free survival (RFS), and overall survival (OS). RESULTS: Of the 154 melanoma samples, 77 (55.4%) were TrkA immunopositive, 81 (58.3%) were TrkB immunopositive, 113 (81.3%) were BDNF immunopositive, and 104 (75.4%) were NGF immunopositive. We found NT/TRK expression associated strongly with several clinical prognostic factors, including the tumor-node-metastasis stage (p < 0.001), histological subtype (p < 0.001), and Clark level (p < 0.05), as well as with a worse OS (p < 0.05 for all, except TrkB) and RFS (p < 0.05 for all). CONCLUSIONS: Our results show strong associations of NT/TRK expression with melanoma stage progression and a poor prognosis.

4 Article Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients. 2016

Escobar, Gabriela F / Arraes, Jose Aroldo A / Bakos, Lucio / Ashton-Prolla, Patricia / Giugliani, Roberto / Callegari-Jacques, Sidia Maria / Santos, Sidney / Bakos, Renato M. ·aDepartment of Dermatology, Hospital de Clínicas de Porto Alegre (HCPA) bDepartment of Genetics, Universidade Federal do Rio Grande do Sul (UFRGS), Experimental Research Center and Medical Genetics Service, HCPA cPostgraduate Program in Medical Sciences dDepartment of Statistics, UFRGS, Porto Alegre eLaboratory of Human and Medical Genetics, Universidade Federal do Pará (UFPA), Belém, Brazil. ·Melanoma Res · Pubmed #27145040.

ABSTRACT: BACKGROUND: Melanoma is the leading cause of death from skin cancers and its etiology is complex. Recent discoveries related to genetic risk factors are helping us to understand melanoma pathogenesis better. Nuclear factor-κB (NF-κB) has a critical role in immunity, inflammation, and tumor growth. The 94ins/del ATTG (rs28362491) polymorphism located in the NFKB1 gene has been associated to various cancers and the ATTG2/ATTG2 genotype was correlated to melanoma risk in Sweden. The CYP19A1 gene encodes the enzyme aromatase, which is active in malignant melanoma tissue. In addition, the CYP19A1 TCT insertion/deletion variant in intron 4 (rs11575899) has been associated with an increased incidence of cancer, albeit with conflicting results. The goal of this study was to investigate possible associations between these two gene variants and melanoma. METHODS: In this case-control study, we evaluated 117 cutaneous melanoma patients and 116 controls from southern Brazil. Genotyping of rs28362491 and rs11575899 was carried out by means of PCR amplification and capillary electrophoresis. Logistic regression was used to obtain odds ratios (ORs) of melanoma, according to genotypes. RESULTS: We identified an association between the ATTG2/ATTG2 and melanoma [OR=1.78; 95% confidence interval (CI): 1.06-3.00; P=0.03]. In addition, there was a dose effect: for each ins allele in the genotype, the risk for melanoma increased (OR=1.51; 95% CI: 1.08-2.11; P=0.017). As regards the CYP19A1 variant, genotype 11 (del/del) was more frequent in patients than in controls (OR=1.85; 95% CI 1.06-3.22; P=0.03). CONCLUSION: The NFKB1 ATTG2/ATTG2 and CYP19A1 del/del genotypes are significantly associated with melanoma and could be genetic markers of melanoma susceptibility in southern Brazilian population.

5 Article Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. 2016

Puig, Susana / Potrony, Miriam / Cuellar, Francisco / Puig-Butille, Joan Anton / Carrera, Cristina / Aguilera, Paula / Nagore, Eduardo / Garcia-Casado, Zaida / Requena, Celia / Kumar, Rajiv / Landman, Gilles / Costa Soares de Sá, Bianca / Gargantini Rezze, Gisele / Facure, Luciana / de Avila, Alexandre Leon Ribeiro / Achatz, Maria Isabel / Carraro, Dirce Maria / Duprat Neto, João Pedreira / Grazziotin, Thais C / Bonamigo, Renan R / Rey, Maria Carolina W / Balestrini, Claudia / Morales, Enrique / Molgo, Montserrat / Bakos, Renato Marchiori / Ashton-Prolla, Patricia / Giugliani, Roberto / Larre Borges, Alejandra / Barquet, Virginia / Pérez, Javiera / Martínez, Miguel / Cabo, Horacio / Cohen Sabban, Emilia / Latorre, Clara / Carlos-Ortega, Blanca / Salas-Alanis, Julio C / Gonzalez, Roger / Olazaran, Zulema / Malvehy, Josep / Badenas, Celia. ·Melanoma Unit, Dermatology Department, Hospital Clínic & IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain. · Centro Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain. · Departament de Medicina, Universitat de Barcelona, Barcelona, Spain. · Consejo Nacional de Ciencia y Tecnología (CONACYT), Ciudad de México, México. · Melanoma Unit, Biochemistry and Molecular Genetics Department, Hospital Clínic & IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain. · Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain. · Universidad Católica de Valencia, Valencia, Spain. · Molecular Biology Unit, Instituto Valenciano de Oncologia, Valencia, Spain. · Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany. · Escola Paulista de Medicina - UNIFESP, São Paulo, Brazil. · International Research Center, AC Camargo Cancer Center, São Paulo, Brazil. · Dermatology Department and Post-Graduation Program of Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil. · Servicio de Dermatología, Hospital Dr. Sótero del Río, Santiago de Chile, Chile. · Servicio de Dermatología, Hospital San Juan de Dios, Santiago, Chile. · Pontificia Universidad Católica de Chile, Santiago de Chile, Chile. · Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. · Unidad de Lesiones Pigmentadas, Cátedra de Dermatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. · Instituto de Investigaciones Medicas "A Lanari," Universidad de Buenos Aires, Buenos Aires, Argentina. · Consultorio Dermatológico Drs. Cohen Sabban y Cabo, Buenos Aires, Argentina. · Hospital Especialidades Centro Medico Nacional La Raza, Mexico, DF, Mexico. · Departamento de Ciencias Básicas, Escuela de Medicina Universidad de Monterrey, Monterrey, Mexico. · Departamento de Introducción a la Clínica, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Mexico. · Servicio de Dermatología, Hospital Universitario "Dr. José Eleuterio González," Monterrey, Mexico. ·Genet Med · Pubmed #26681309.

ABSTRACT: PURPOSE: CDKN2A is the main high-risk melanoma-susceptibility gene, but it has been poorly assessed in Latin America. We sought to analyze CDKN2A and MC1R in patients from Latin America with familial and sporadic multiple primary melanoma (SMP) and compare the data with those for patients from Spain to establish bases for melanoma genetic counseling in Latin America. METHODS: CDKN2A and MC1R were sequenced in 186 Latin American patients from Argentina, Brazil, Chile, Mexico, and Uruguay, and in 904 Spanish patients. Clinical and phenotypic data were obtained. RESULTS: Overall, 24 and 14% of melanoma-prone families in Latin America and Spain, respectively, had mutations in CDKN2A. Latin American families had CDKN2A mutations more frequently (P = 0.014) than Spanish ones. Of patients with SMP, 10% of those from Latin America and 8.5% of those from Spain had mutations in CDKN2A (P = 0.623). The most recurrent CDKN2A mutations were c.-34G>T and p.G101W. Latin American patients had fairer hair (P = 0.016) and skin (P < 0.001) and a higher prevalence of MC1R variants (P = 0.003) compared with Spanish patients. CONCLUSION: The inclusion criteria for genetic counseling of melanoma in Latin America may be the same criteria used in Spain, as suggested in areas with low to medium incidence, SMP with at least two melanomas, or families with at least two cases among first- or second-degree relatives.Genet Med 18 7, 727-736.

6 Article Correlation between Breslow thickness and Technetium-99m-sestamibi uptake in cutaneous melanoma. 2013

Masiero, Nathália / Costa, Manuela Martins / Masiero, Paulo Ricardo / Rosa, Luciana / Bakos, Renato / Cartell, Andre / Migliavacca, Alceu / Bakos, Lucio. ·Department of Dermatology. ·Eur J Dermatol · Pubmed #23816542.

ABSTRACT: BACKGROUND: Technetium-99m-sestamibi (MIBI) is a radiopharmaceutical that has well-known tumor-seeking properties. We evaluated the correlation between Breslow thickness and MIBI uptake by cutaneous melanoma (CM). MATERIAL AND METHODS: Patients with suspicious melanocytic lesions received intravenous injections of 740-1,110 Mbq of MIBI. Using a gamma probe, the number of radioactive counts in the skin was considered to determinate the MIBI uptake intensity. SPECT imaging of the lesion site and respective lymph node region was obtained. RESULTS: There was a strong positive correlation between MIBI uptake intensity and Breslow thickness (rs = 0.74, P = 0.003). There was a statistically significant difference (P <0.001) between lesions with Breslow thickness <1 mm (MIBI uptake intensity = 1.23 ± 0.28 radioactive counts) and Breslow thickness >1 mm (MIBI uptake intensity = 2.32 ± 0.32 radioactive counts). DISCUSSION: The possibility of correlating MIBI uptake intensity with Breslow categories may facilitate surgical procedures, reducing morbidity and costs.

7 Article Accuracy in melanoma detection: a 10-year multicenter survey. 2012

Argenziano, Giuseppe / Cerroni, Lorenzo / Zalaudek, Iris / Staibano, Stefania / Hofmann-Wellenhof, Rainer / Arpaia, Nicola / Bakos, Renato Marchiori / Balme, Brigitte / Bandic, Jadran / Bandelloni, Roberto / Brunasso, Alexandra M G / Cabo, Horacio / Calcara, David A / Carlos-Ortega, Blanca / Carvalho, Ana Carolina / Casas, Gabriel / Dong, Huiting / Ferrara, Gerardo / Filotico, Raffaele / Gómez, Guillermo / Halpern, Allan / Ilardi, Gennaro / Ishiko, Akira / Kandiloglu, Gulsen / Kawasaki, Hiroshi / Kobayashi, Ken / Koga, Hiroshi / Kovalyshyn, Ivanka / Langford, David / Liu, Xin / Marghoob, Ashfaq A / Mascolo, Massimo / Massone, Cesare / Mazzoni, Laura / Menzies, Scott / Minagawa, Akane / Nugnes, Loredana / Ozdemir, Fezal / Pellacani, Giovanni / Seidenari, Stefania / Siamas, Katherine / Stanganelli, Ignazio / Stoecker, William V / Tanaka, Masaru / Thomas, Luc / Tschandl, Philipp / Kittler, Harald. ·Dermatology Unit, Medical Department, Arcispedale Santa Maria Nuova, Viale Risorgimento 80 - 42100 Reggio Emilia, Italy. g.argenziano@gmail.com ·J Am Acad Dermatol · Pubmed #21982636.

ABSTRACT: BACKGROUND: Early excision is the only strategy to reduce melanoma mortality, but unnecessary excision of benign lesions increases morbidity and healthcare costs. OBJECTIVE: To assess accuracy in melanoma detection based on number-needed-to-excise (NNE) values over a 10-year period. METHODS: Information was retrieved on all histopathologically confirmed cutaneous melanomas or melanocytic nevi that were excised between 1998 and 2007 at participating clinics. NNE values were calculated by dividing the total number of excised lesions by the number of melanomas. Analyses included changes in NNE over time, differences in NNE between specialized clinical settings (SCS) versus non-specialized clinical settings (NSCS), and patient factors influencing NNE. RESULTS: The participating clinics contributed a total of 300,215 cases, including 17,172 melanomas and 283,043 melanocytic nevi. The overall NNE values achieved in SCS and NSCS in the 10-year period were 8.7 and 29.4, respectively. The NNE improved over time in SCS (from 12.8 to 6.8), but appeared unchanged in NSCS. Most of the effect on NNE in SCS was due to a greater number of excised melanomas. Higher NNE values were observed in patients younger than 40 years and for lesions located on the trunk. LIMITATIONS: No data concerning the use of dermatoscopy and digital monitoring procedures were collected from the participating centers. CONCLUSION: Over the 10-year study period, accuracy in melanoma detection improved only in specialized clinics maybe because of a larger use of new diagnostic techniques such as dermatoscopy.

8 Article The CDKN2A p.A148T variant is associated with cutaneous melanoma in Southern Brazil. 2011

Bakos, Renato M / Besch, Robert / Zoratto, Gabriela G / Godinho, Janaína M / Mazzotti, Nicolle G / Ruzicka, Thomas / Bakos, Lucio / Santos, Sidney E / Ashton-Prolla, Patricia / Berking, Carola / Giugliani, Roberto. ·Dermatology Service, Hospital de Clínicas de Porto Alegre (HCPA), Brazil. ·Exp Dermatol · Pubmed #21895773.

ABSTRACT: Several germline mutations and sequence variants in cancer predisposition genes have been described. Among these, the CDKN2A p.A148T variant appears to be frequent in patients with melanoma, at least in certain ethnic groups. In this case-control study, we evaluated 127 patients with cutaneous melanoma and 128 controls from Southern Brazil, the region with the highest melanoma incidence rates in the country. Using PCR-RFLP, we demonstrate that CDKN2A p.A148T variant was significantly more frequent in patients with melanoma than in controls (12.6% vs 3.9%; P=0.009). There was no association between presence of the polymorphism and tumor thickness, site of the primary tumor, melanoma subtype, age at diagnosis, quantitative and qualitative number of nevi. Patients with a positive family of history for other cancers were particularly prone to carry the CDKN2A p.A148T allele. All patients with p.A148T-positive melanoma reported European ancestry, especially German, and this was confirmed using a panel of ancestry-informative INDELs. Our data suggest that CDKN2A p.A148T is a melanoma susceptibility allele in Southern Brazil and is particularly common in patients with melanoma of predominantly European ancestry.

9 Article Predictors of quality of life in patients with skin melanoma at the dermatology department of the Porto Alegre Teaching Hospital. 2011

Barbato, Mariana Tremel / Bakos, Lucio / Bakos, Renato Marchiori / Prieb, Rita / Andrade, Cláudia Dickel de. ·Dermatology Department, Teaching Hospital, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Rio Grande do Sul, Brazil. maribarbato@yahoo.com.br ·An Bras Dermatol · Pubmed #21603807.

ABSTRACT: BACKGROUNDS: Some symptoms present in melanoma patients are directly related to psychological stress, which emphasizes the need to evaluate quality of life (QoL) in these patients at all the stages of their disease. OBJECTIVES: The objective of this study was to evaluate quality of life in a sample of patients diagnosed with melanoma, using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire. METHODS: A descriptive, cross sectional study was conducted between July and December, 2006 with all patients with skin melanoma receiving follow-up care at the Department of Dermatology of the Porto Alegre Teaching Hospital, Federal University of Rio Grande do Sul. RESULTS: Sixty patients were included in the study. Mean age was 55.6 years. Poor education level (primary school or less) was associated with a poorer FACT-G score. Patients with a family history of the disease had higher QoL scores in 3 of the 4 categories evaluated: physical, emotional and functional wellbeing (p<0.01). QoL scores were higher in married patients (82.42) compared to single patients (70.28) (p<0.01). Patients with metastases had lower scores in the functional wellbeing category and this difference was statistically significant. CONCLUSIONS: Factors related to the tumor, as well as gender, age and employment status, were not found to be predictive of quality of life in this sample. Quality of life scores were lower in the functional wellbeing domain in patients with metastases. Married patients are able to count on greater comfort and emotional support to help them deal with the diagnosis of melanoma. Patients with a family history of melanoma had significantly higher quality of life scores, while those with poor education levels had lower scores.

10 Article [A rare case of local relapsing oral melanoma]. 2010

Gauwerky, Katharina J / Ehrenfeld, Michael / Bakos, Renato M / Volkenandt, Matthias / Ruzicka, Thomas / Berking, Carola. ·Klinik und Poliklinik für Dermatologie und Allergologie, LMU München. ·J Dtsch Dermatol Ges · Pubmed #20163505.

ABSTRACT: Melanoma of the oral mucosa is an extremely rare tumor. At the time of diagnosis most melanomas are in an advanced stage because of few clinical signs. Therefore the prognosis of melanoma of the oral mucosa is often very poor. We present a 48-year-old patient with melanoma of the oral mucosa first diagnosed 22 years ago. Over 20 years several wide excisions were necessary because of multiple local relapses. Eventually, the patient died from brain metastases.